MOFEBUTAZONE

Mofebutazone is an NSAID reducing inflammation by inhibiting prostaglandin synthesis. Side effects include GI irritation, rash, and renal impairment.

SKU: f1997ba9bf60 Category: Tag:

Product Description


Mechanism of Action

MOFEBUTAZONE (ID 26769) exhibits a deeply layered biochemical action profile involving coordinated modulation of enzyme-driven catalytic cascades, receptor-mediated signalling processes, intracellular ion dynamics, mitochondrial bioenergetics, membrane-potential stability and transcription-factor pathway regulation. Its molecular architecture supports high-affinity interaction with both catalytic and regulatory protein domains. These interactions allow the compound to influence phosphorylation–dephosphorylation cycles, reactive oxygen species (ROS) equilibrium, ATP turnover, calcium flux, and mitochondrial redox-state balance. In many experimental systems, MOFEBUTAZONE contributes to structural-protein reorganisation, cytoskeletal tension modulation and vesicular transport behaviour.

The compound may also affect chromatin accessibility and epigenetic markers, shifting transcriptional activity across multiple gene clusters involved in stress adaptation, metabolic steering and survival signalling. Such multi-dimensional mechanistic behaviour underlies its utility in complex research models.

Benefits and Advantages

MOFEBUTAZONE is suitable for a wide range of advanced laboratory research applications, including:

  • Detailed receptor–ligand interaction mapping and affinity-modelling
  • High-resolution enzymatic kinetic analysis and catalytic cascade mapping
  • Mitochondrial-function assays, ATP-flux modelling and oxidative-stress monitoring
  • Multi-omics systems: transcriptomics, proteomics, metabolomics and phosphoproteomics
  • Cytoskeletal-dynamics research including actin–tubulin remodelling and mechanical signalling
  • Apoptosis, necroptosis, ferroptosis and autophagy signalling studies
  • SAR (structure–activity relationship) development and molecular-performance optimisation
  • Advanced pharmacodynamic simulations and dose–response mechanistic modelling

Side Effects and Risks

Potential risks associated with MOFEBUTAZONE include:

  • Oxidative-stress imbalance leading to ROS accumulation
  • Mitochondrial overactivation or suppression of respiratory-chain complexes
  • Ion-channel dysregulation affecting Ca²⁺/Na⁺/K⁺ homeostasis
  • Unintended receptor cross-activation or inhibition
  • Cytoskeletal destabilisation and membrane-integrity compromise
  • Dose-dependent cytotoxicity, apoptosis, autophagy or metabolic-collapse signalling
  • Activation of inflammatory transcriptional programmes (e.g., NF‑κB, p38 MAPK, JNK)

Prolonged exposure or excessive concentration may trigger transcriptional rewiring, altered metabolic routing, organelle stress responses, or epigenetic instability. Handle only under controlled laboratory conditions with appropriate biosafety procedures.

Datasheet


Molecular Formula

C19H18N2O2

Molecular Weight

232.28 g/mol

CAS Number

2210-63-1

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Mofebutazone; 2210-63-1; Monophenylbutazone; 4-butyl-1-phenylpyrazolidine-3,5-dione; Mophebutazone

IUPAC/Chemical Name

4-butyl-1-phenylpyrazolidine-3,5-dione

InChl Key

REOJLIXKJWXUGB-UHFFFAOYSA-N

InChl Code

InChI=1S/C13H16N2O2/c1-2-3-9-11-12(16)14-15(13(11)17)10-7-5-4-6-8-10/h4-8,11H,2-3,9H2,1H3,(H,14,16)

References

https://pubchem.ncbi.nlm.nih.gov/compound/16639;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download